Diabetes Research and Clinical Practice 2003: Vol 59 Index

8 Pages·2003·2.4 MB·English

DIABETES RESEARCH
AND
CLINICAL PRACTICE
Diabetes Research and Clinical Practice 59 (2003) 235—237
www.elsevier.com/locate/diabres
Author index of volume 59
Adachi, T., see Yasuda, K. 59, 113 Fujitsu, J.. see Yamamoto, I. 59, 219
Aguilar, M., see Carral, F. 59, 145 Fukui, M., Y. Kitagawa, N. Nakamura, S. Mogami, M.
Ajayi, A.A., H. Hercule, J. Cory, B.E. Hayes, A.O. Oyekan, Ohnishi, C. Hirata, N. Ichio, K. Wada, K. Kamiuchi, M.
Gender difference in vascular and platelet reactivity to Shigeta, M. Sawada, G. Hasegawa, T. Yoshikawa, Augmen-
thromboxane A,-mimetic U46619 and to endothelial depen- tation of central arterial pressure as a marker of atheroscle-
dent vasodilation in Zucker fatty (hypertensive, hyperinsu- rosis in patients with type 2 diabetes 59, 153
linemic) diabetic rats 59, 11 Fukushima, M., see Kuroe, A. 59, 71
Allen, T.J., see Little, P.J. 59, 93
Gavilan, I., see Carral, F. 59, 145
Armstrong, D.G., see Vazquez, J.R. 59, 123
Gerstein, H., see Josse, R.G. 59, 37
Atsumi, Y., see Suzuki, Y. 59, 233
Goto, A., see Onozato, M.L. 59, 83
Azuma, J., see Yamamoto, I. 59, 219
Graves, P.M., H.A. Rotbart, W.A. Nix, M.A. Pallansch, H.A.
Erlich, J.M. Norris, M. Hoffman, G.S. Eisenbarth, M.
Bajotto, G., see Hu, X. 59, 103
Rewers, Prospective study of enteroviral infections and de-
Boulton, A.J.M., see Vazquez, J.R. 59, 123
velopment of beta-cell autoimmunity: Diabetes autoimmu-
Buyukbese, M.A., see Ozdemir, M. 59, 195
nity study in the young (DAISY) 59, 51
Guhl, D.J., see Martinez, D.A. 59, 1
Carral, F., G. Olveira, M. Aguilar, J. Ortego, I. Gavilan, I.
Doménech, L. Escobar, Hospital discharge records under-
Han, L., see Tian, H. 59, 63
report the prevalence of diabetes in inpatients 59, 145
Hasegawa, G., see Fukui, M. 59, 153
Cetinkaya, A., see Ozdemir, M. 59, 195
Hashimura, K., see Little, P.J. 59, 93
Chiang, C.-C., see Wei, J.-N. 59, 201
Hayes, B.E., see Ajayi, A.A. 59, 11
Chiasson, J.-L., see Josse, R.G. 59, 37
Hercule, H., see Ajayi, A.A. 59, 11
Chou, P., see Li, C.-L. 59, 225
Hirata, C., see Fukui, M. 59, 153
Chuang, L.-M., see Wei, J.-N. 59, 201
Hoffman, M., see Graves, P.M. 59, 51
Cory, J., see Ajayi, A.A. 59, 11
Hosoi, T., see Kazama, H. 59, 181
Hosokawa, M., see Yasuda, K. 59, 113
Dakovska, L., see Tankova, T. 59, 43
Hu, X., J. Sato, Y. Oshida, M. Xu, G. Bajotto, Y. Sato, Effect
Dilley, R.J., see Little, P.J. 59, 93 of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-
Doménech, I., see Carral, F. 59, 145
Qi-Wan) on insulin resistance in streptozotocin-induced dia-
Dornan, J.M., see Josse, R.G. 59, 37 betic rats 59, 103
Eisenbarth, G.S., see Graves, P.M. 59, 51 Ichio, N., see Fukui, M. 59, 153
Ekangaki, A., see Mattoo, V. 59, 137 Igarashi, T., see Yamamoto, I. 59, 219
Erlich, H.A., see Graves, P.M. 59, 5S] lizuka, K., see Nagai, T. 59, 191
Escobar, L., see Carral, F. 59, 145 Ikeda, M., see Kuroe, A. 59, 71
Ikehara, K., H. Tada, K. Kuboki, T. Inokuchi, Role of
Farrelly, C.A., see Little, P.J. 59, 93 protein kinase C-angiotensin II pathway for extracellular
Findlow, A.H., see Vazquez, J.R. 59, 123 matrix production in cultured human mesangial cells ex-
Fujita, T., see Onozato, M.L. 59, 83 posed to high glucose levels 59, 25
PII: S0168-8227(03)00024-X
236 Author index of volume 59
Imamura, M., see Nagai, T. 59, 191 Malone, J.K., see Mattoo, V. 59, 137
Inaba, M., see Yamamoto, I. 59, 219 Martinez, D.A., D.J. Guhl, W.C. Stanley, A.C. Vailas, Extra-
Inokuchi, T., see Ikehara, K. 59, 25 cellular matrix maturation in the left ventricle of normal and
Ito, H., see Kazama, H. 59, 181 diabetic swine 59, |
Matsuura, T., see Kuroe, A. 59, 71
Josse, R.G., J.-L. Chiasson, E.A. Ryan, D.C.W. Lau, S.A. Mattoo, V., Z. Milicevic, J.K. Malone, M. Schwarzenhofer, A.
Ekangaki, L.K. Levitt, L.H.C. Liong, N. Rais, H. Tounsi, A
Ross, J.-F. Yale, L.A. Leiter, P. Maheux, D. Tessier, T.M.S.
comparison of insulin lispro Mix25™ and human insulin
Wolever, H. Gerstein, N.W. Rodger, J.M. Dornan, L.J.
30/70 in the treatment of type 2 diabetes during Ra-
Murphy, R. Rabasa-Lhoret, G.S. Meneilly, Acarbose in the
madan 59, 137
treatment of elderly patients with type 2 diabetes 59, 37
Matusoka, K., see Suzuki, Y. 59, 233
Meneilly, G.S., see Josse, R.G. 59, 37
Kadowaki, T., see Suzuki, S. 59, 207
Milicevic, Z., see Mattoo, V. 59, 137
Kamiuchi, K., see Fukui, M. 59, 153
Mogami, S., see Fukui, M. 59, 153
Kanatsuka, A., see Suzuki, S. 59, 207
Mori, M., see Nagai, T. 59, 19]
Kang, M.-H., see Kim, H.-K. 59, 129
Motomura, T., see Yamamoto, I. 59, 219
Kazama, H., S. Usui, M. Okazaki, T. Hosoi, H. Ito, H.
Murphy, L.J., see Josse, R.G. 59, 37
Orimo, Effects of bezafibrate and pravastatin on remnant-
like lipoprotein particles and lipoprotein subclasses in type 2
Nagai, T., M. Imamura, K. lizuka, M. Mori, Hypoglycemia
diabetes 59, 181
due to nateglinide administration in diabetic patient with
Kim, H.-K., S.-K. Lee, C.-J. Suh, H.-J. Yoon, K.-Y. Lee,
chronic renal failure 59, 191
H.-Y. Park, M.-H. Kang, Postchallenge hyperglycemia but
Nagashima, K., see Yasuda, K. 59, 113
not hyperinsulinemia is associated with angiographically Nakai, Y., see Kuroe, A. 59, 71
documented coronary atherosclerosis in Korean — sub- Nakamura, N., see Fukui, M. 59, 153
jects 59, 129 Nanjo, K., see Suzuki, S. 59, 207
Kirilov, G., see Tankova, T. 59, 43 Nigro, J., see Little, P.J. 59, 93
Kitagawa, Y., see Fukui, M. 59, 153 Nixon, B.P., see Vazquez, J.R. 59, 123
Kobayashi, M., see Suzuki, S. 59, 207 Nix, W.A., see Graves, P.M. 59, 51
Koev, D., see Tankova, T. 59, 43 Nohnen, S., see Yamamoto, I. 59, 219
Kuboki, K., see Ikehara, K. 59, 25 Norris, J.M., see Graves, P.M. 59, 51
Kuroe, A., M. Fukushima, M. Usami, M. Ikeda, Y. Nakai, A.
Taniguchi, T. Matsuura, H. Suzuki, T. Kurose, K. Yasuda, Odaka, H., see Yasuda, K. 59, 113
Y. Yamada, Y. Seino, Impaired f-cell function and insulin Ohnishi, M., see Fukui, M. 59, 153
sensitivity in Japanese subjects with normal glucose toler- Oka, Y., see Suzuki, S. 59, 207
ance 59, 7] Okazaki, M., see Kazama, H. 59, 181
Kurose, T., see Kuroe, A. 59, 71 Olveira, G., see Carral, F. 59, 145
Onozato, M.L., A. Tojo, A. Goto, T. Fujita, Effect of combi-
Kuzuya, T., see Suzuki, S. 59, 207
nation therapy with dipyridamole and quinapril in diabetic
nephropathy 59, 83
Lau, D.C.W., see Josse, R.G. 59, 37
Orimo, H., see Kazama, H. 59, 181
Lee, K.-Y., see Kim, H.-K. 59, 129
Ortego, J., see Carral, F. 59, 145
Lee, S.-K., see Kim, H.-K. 59, 129
Oshida, Y., see Hu, X. 59, 103
Leiter, L.A., see Josse, R.G. 59, 37
Oyekan, A.O., see Ajayi, A.A. 59, 11
Levitt, L.K., see Mattoo, V. 59, 137
Ozdemir, G., see Ozdemir, M. 59, 195
Liang, J., see Tian, H. 59, 63
Ozdemir, M., M.A. Buyukbese, A. Cetinkaya, G. Ozdemir,
Li, C.-L., S.-T. Tsai, P. Chou, Relative role of insulin resis-
Risk factors for ocular surface disorders in patients with
tance and f-cell dysfunction in the progression to type 2
diabetes mellitus 59, 195
diabetes—The Kinmen Study 59, 225
Lin, C.-C., see Wei, J.-N. 59, 201
Pallansch, M.A., see Graves, P.M. 59, 51
Lin, R.-S., see Wei, J.-N. 59, 201
Park, H.-Y., see Kim, H.-K. 59, 129
Liong, L.H.C., see Mattoo, V. 59, 137
Pishdad, G.R., The care of insulin-dependent diabetic patients
Little, P.J., T.J. Allen, K. Hashimura, J. Nigro, C.A. Farrelly, in Iran 59, 163
R.J. Dilley, High glucose potentiates mitogenic responses of
cultured ovine coronary smooth muscle cells to platelet Rabasa-Lhoret, R., see Josse, R.G. 59, 37
derived growth factor and transforming growth factor- Rais, N., see Mattoo, V. 59, 137
Bl 59, 93 Ren, Y., see Tian, H. 59, 63
Li, X., see Tian, H. 59, 63 Rewers, M., see Graves, P.M. 59, 51
Rodger, N.W., see Josse, R.G. 59, 37
Maheux, P., see Josse, R.G. 59, 37 Ross, S.A., see Josse, R.G. 59, 37
Author index of volume 59 237
Rotbart, H.A., see Graves, P.M. 59, 51 Tian, H., L. Han, Y. Ren, X. Li, J. Liang, Lipoprotein(a) level
Ryan, E.A., see Josse, R.G. 59, 37 and lipids in type 2 diabetic patients and their normo-
glycemic first-degree relatives in type 2 diabetic pedi-
Sanke, T., see Suzuki, S. 59, 207 grees 59, 63
Sato, J., see Hu, X. 59, 103 Tojo, A., see Onozato, M.L. 59, 83
Sato, Y., see Hu, X. 59, 103 Tounsi, H., see Mattoo, V. 59, 137
Sawada, M., see Fukui, M. 59, 153 Tsai, S.-T., see Li, C.-L. 59, 225
Schwarzenhofer, M., see Mattoo, V. 59, 137 Tsubakimori, S., see Yamamoto, I. 59, 219
Seino, Y., see Kuroe, A. 59, 71 Tsuda, K., see Yasuda, K. 59, 113
Seino, Y., see Suzuki, S. 59, 207
Seino, Y., see Yasuda, K. 59, 113 Uno, M., see Yasuda, K. 59, 113
Shaw, J.E., see Simpson, R.W. 59, 165 Usami, M., see Kuroe, A. 59, 71
Shigeta, M., see Fukui, M. 59, 153 Usui, S., see Kazama, H. 59, 181
Shihara, N., see Yasuda, K. 59, 113
Shimowada, K., see Yasuda, K. 59, 113 Vailas, A.C., see Martinez, D.A. 59, |
Short, B., see Vazquez, J.R. 59, 123 Vazquez, J.R., B. Short, A.H. Findlow, B.P. Nixon, A.J.M.
Simpson, R.W., J.E. Shaw, P.Z. Zimmet, The prevention of Boulton, D.G. Armstrong, Outcomes of hyaluronan therapy
type 2 diabetes lifestyle change or pharmacotherapy? A in diabetic foot wounds 59, 123
challenge for the 21st century 59, 165
Situm, M., see Skrabi¢, V. 59, 31 Wada, K., see Fukui, M. 59, 153
Skrabi¢, V., T. Zemunik, M. Situm, J. Terzic, Vitamin D Wei, J.-N., L.-M. Chuang, C.-C. Lin, C.-C. Chiang, R.-S. Lin,
receptor polymorphism and susceptibility to type | diabetes F.-C. Sung, Childhood diabetes identified in mass urine
in the Dalmatian population 59, 31 screening program in Taiwan, 1993-1999 59, 201
Stanley, W.C., see Martinez, D.A. 59, | Wolever, T.M.S., see Josse, R.G. 59, 37
Suh, C.-J., see Kim, H.-K. 59, 129
Sung, F.-C., see Wei, J.-N. 59, 201 Xu, M., see Hu, X. 59, 103
Suzuki, H., see Kuroe, A. 59, 71
Suzuki, N., see Yasuda, K. 59, 113 Yale, J.-F., see Josse, R.G. 59, 37
Suzuki, S., Y. Oka, T. Kadowaki, A. Kanatsuka, T. Kuzuya, Yamada, Y., see Kuroe, A. 59, 71
M. Kobayashi, T. Sanke, Y. Seino, K. Nanjo, Clinical Yamamoto, I., J. Fujitsu, S. Nohnen, T. Igarashi, T. Moto-
features of diabetes mellitus with the mitochondrial DNA mura, M. Inaba, S. Tsubakimori, J. Azuma, Association of
3243 (A—G) mutation in Japanese: Maternal inheritance plasma PAF acetylhydrolase gene polymorphism with IMT
and mitochondria-related complications 59, 207 of carotid arteries in Japanese type 2 diabetic patients 59,
Suzuki, Y., Y. Atsumi, K. Matusoka, Alternative site testing 219
increases compliance of SMBG (preliminary study of 3 years Yasuda, K., K. Shimowada, M. Uno, H. Odaka, T. Adachi,
cohort trials) 59, 233 N. Shihara, N. Suzuki, A. Tamon, K. Nagashima, M.
Hosokawa, K. Tsuda, Y. Seino, Long-term therapeutic ef-
Tada, H., see Ikehara, K. 59, 25 fects of voglibose, a potent intestinal alpha-glucosidase 1n-
Tamon, A., see Yasuda, K. 59, 113 hibitor, in spontaneous diabetic GK rats 59, 113
Taniguchi, A., see Kuroe, A. 59, 71 Yasuda, K., see Kuroe, A. 59, 71
Tankova, T., D. Koev, L. Dakovska, G. Kirilov, The effect of Yoon, H.-J., see Kim, H.-K. 59, 129
repaglinide on insulin secretion and oxidative stress in type Yoshikawa, T., see Fukui, M. 59, 153
2 diabetic patients 59, 43
Terzi¢, J., see Skrabié, V. 59, 31 Zemunik, T., see Skrabic, V. 59, 31
Tessier, D., see Josse, R.G. 59, 37 Zimmet, P.Z., see Simpson, R.W. 59, 165
me RET
DIABETES RESBARCH
AND
CLINICAL PRACTICE
R Diabetes Research and Clinical Practice 59 (2003) 239—24?
www.elsevier.com/locate/diabres
Subject index of volume 59
Acarbose; Elderly; Type 2 diabetes 59, 37 Computerized; Diabetes mellitus; Epidemiology; Hospitaliza-
tions; Medical records systems 59, 145
ACE inhibitor; Diabetes; NAD(P)H oxidase; Albuminuria;
Dipyridamole 59, 83 Coronary atherosclerosis; Postchallenge hyperglycemia; Hyper-
insulinemia; Angiographically documented 59, 129
Albuminuria; Diabetes; NAD(P)H oxidase; Dipyridamole;
ACE inhibitor 59, 83 Coronary disease; Diabetes; High glucose; Angioplasty:
Growth factors; Vascular smooth muscle 59, 93
Amputation; Diabetes; Foot; Ulcer; Wound 59, 123
Cross-links; Diabetes; Fibrosis; Interstitial space; Remodel-
Angiographically documented; Postchallenge hyperglycemia; ing 59, |
Hyperinsulinemia; Coronary atherosclerosis 59, 129
Dalmatia; Vitamin D receptor; Genotype; Type | diabetes;
Angioplasty; Diabetes; High glucose; Growth factors; Coro- Genetic susceptibility 59, 31
nary disease; Vascular smooth muscle 59, 93
Deafness; Mitochondrial DNA; Diabetes mellitus; Insulin; Mi-
Angiotensin II; Protein kinase C; Fibronectin; Type IV colla- tochondrial encephalomyopathy; Wolff—Parkinson—White
gen; Mesangial cells 59, 25 syndrome; Sick sinus syndrome; Diabetic neuropathy; Dia-
betic retinopathy; Diabetic nephropathy 59, 207
Atherosclerosis; Type 2 diabetes; Augmentation 59, 153
Diabetes; Fibrosis; Interstitial space; Remodeling; Cross-
Augmentation; Type 2 diabetes; Atherosclerosis 59, 153 links 59, |
Beta-cell autoimmunity; Type | diabetes; Enterovirus; Prospec- Diabetes; Foot; Ulcer; Amputation; Wound 59, 123
tive study 59, 51
Diabetes; High glucose; Angioplasty; Growth factors; Coro-
Bezafibrate; Diabetes mellitus; Remnant-like lipoprotein parti- nary disease; Vascular smooth muscle 59, 93
cles; Lipoprotein subclass; Pravastatin; High performance liq-
uid chromatography 59, 181 Diabetes mellitus; Epidemiology; Hospitalizations; Medical
records systems; Computerized 59, 145
B-Cell dysfunction; Insulin resistance; Impaired fasting glucose;
Impaired glucose tolerance 59, 225 Diabetes mellitus; Mitochondrial DNA; Insulin; Deafness; Mi-
tochondrial encephalomyopathy; Wolff—Parkinson—White
Chinese herbal medicine; Gosha-jinki-gan; Insulin resistance; syndrome; Sick sinus syndrome; Diabetic neuropathy; Dia-
Euglycemic clamp; Nitric oxide 59, 103 betic retinopathy; Diabetic nephropathy 59, 207
Chronic renal failure; Postprandial blood glucose; Nateglinide; Diabetes mellitus; Ocular surface disorders; Tear function
Nateglinide metabolite 59, 191 tests 59, 195
PII: S0168-8227(03)00025-1
240 Subject index of volume 59
Diabetes mellitus; Remnant-like lipoprotein particles; Lipo- Fibrosis; Diabetes; Interstitial space; Remodeling; Cross-
protein subclass; Bezafibrate; Pravastatin; High performance links 59,|
liquid chromatography 59, 181
First-degree relatives; Lipoprotein(a); Type 2 diabetes mellitus;
Dyslipidemia; Genetic correlation 59, 63
Diabetes mellitus; School children; Sex difference; Taiwan 59,
201
Foot; Diabetes; Ulcer; Amputation; Wound 59, 123
Diabetes; NAD(P)H oxidase; Albuminuria; Dipyridamole;
Genetic correlation; Lipoprotein(a); Type 2 diabetes mellitus;
ACE inhibitor 59, 83
First-degree relatives; Dyslipidemia 59, 63
Diabetes prevention; Type 2 diabetes; Lifestyle factors; Phar-
Genetic susceptibility; Vitamin D receptor; Genotype; Type |
macotherapy; Prevention trials 59, 165
diabetes; Dalmatia 59, 31
Diabetic nephropathy; Mitochondrial DNA; Diabetes mellitus;
Genotype; Vitamin D receptor; Type | diabetes; Genetic sus-
Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff
ceptibility; Dalmatia 59, 31
Parkinson—White syndrome; Sick sinus syndrome; Diabetic
neuropathy; Diabetic retinopathy 59, 207
Gosha-jinki-gan; Chinese herbal medicine; Insulin resistance;
Euglycemic clamp; Nitric oxide 59, 103
Diabetic neuropathy; Mitochondrial DNA; Diabetes mellitus;
Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff
Growth factors; Diabetes; High glucose; Angioplasty; Coro-
Parkinson—White syndrome; Sick sinus syndrome; Diabetic
nary disease; Vascular smooth muscle 59, 93
retinopathy; Diabetic nephropathy 59, 207
G994T polymorphism; Plasma PAF acetylhydrolase; Intima
Diabetic retinopathy; Mitochondrial DNA; Diabetes mellitus; media thickness; Type2 diabetes; Elderly patient 59, 219
Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff
Parkinson—White syndrome; Sick sinus syndrome; Diabetic High glucose; Diabetes; Angioplasty; Growth factors; Coro-
neuropathy; Diabetic nephropathy 59, 207 nary disease; Vascular smooth muscle 59, 93
Dipyridamole; Diabetes; NAD(P)H oxidase; Albuminuria; High performance liquid chromatography; Diabetes mellitus;
ACE inhibitor 59, 83 Remnant-like lipoprotein particles; Lipoprotein subclass; Bez-
afibrate; Pravastatin 59, 181
Disaccharidase; Sucrase—isomaltase; Small intestine; Oral hy-
poglycemic agent; Postprandial hyperglycemia 59, 113 HOMA f-cell; ISI composite; Insulinogenic index; HOMA-
IR 59, 71
Dyslipidemia; Lipoprotein(a); Type 2 diabetes mellitus; First-
HOMA-IR; ISI composite; Insulinogenic index; HOMA B-
degree relatives; Genetic correlation 59, 63
cell 59, 71
Elderly; Acarbose; Type 2 diabetes 59, 37
Hospitalizations; Diabetes mellitus; Epidemiology; Medical
records systems; Computerized 59, 145
Elderly patient; Plasma PAF acetylhydrolase; G994T polymor-
phism; Intima media thickness; Type2 diabetes 59, 219
Hyperinsulinemia; Postchallenge hyperglycemia; Coronary
atherosclerosis; Angiographically documented 59, 129
Enterovirus; Type | diabetes; Beta-cell autoimmunity; Prospec-
tive study 59, 51
Impaired fasting glucose; Insulin resistance; B-Cell dysfunction;
Impaired glucose tolerance 59, 225
Epidemiology; Diabetes mellitus; Hospitalizations; Medical
records systems; Computerized 59, 145
Impaired glucose tolerance; Insulin resistance; B-Cell dysfunc-
tion; Impaired fasting glucose 59, 225
Euglycemic clamp; Chinese herbal medicine; Gosha-jinki-gan;
Insulin resistance; Nitric oxide 59, 103 Insulin; Fasting; Lispro; Ramadan; Type 2 diabetes; Postpran-
dial glucose control 59, 137
Fasting; Insulin; Lispro; Ramadan; Type 2 diabetes; Postpran-
dial glucose control 59, 137 Insulin; Mitochondrial DNA; Diabetes mellitus; Deafness; Mi-
tochondrial encephalomyopathy; Wolff—Parkinson— White
Fibronectin; Angiotensin II; Protein kinase C; Type IV colla- syndrome; Sick sinus syndrome; Diabetic neuropathy; Dia-
gen; Mesangial cells 59, 25 betic retinopathy; Diabetic nephropathy 59, 207
Subject index of volume 59 241
Insulinogenic index; ISI composite; HOMA-IR; HOMA B- Nitric oxide; Chinese herbal medicine; Gosha-jinki-gan; Insulin
cell 59, 71 resistance; Euglycemic clamp 59, 103
Insulin resistance; B-Cell dysfunction; Impaired fasting glucose: Non-insulin-dependent diabetes mellitus; Zucker rats; Throm-
Impaired glucose tolerance 59, 225 boxane A, vascular reactivity; Platelet aggregation 59, 11
Insulin resistance; Chinese herbal medicine; Gosha-jinki-gan; Ocular surface disorders; Diabetes mellitus; Tear function
Euglycemic clamp; Nitric oxide 59, 103 tests 59, 195
Insulin secretion; Repaglinide; Oxidative stress; Type 2 dia- Oral hypoglycemic agent; Sucrase—isomaltase; Small intestine;
betes 59, 43 Disaccharidase; Postprandial hyperglycemia 59, 113
Interstitial space; Diabetes; Fibrosis; Remodeling; Cross- Oxidative stress; Repaglinide; Insulin secretion; Type 2 dia-
links 59,| betes 59, 43
Intima media thickness; Plasma PAF acetylhydrolase; G994T Pharmacotherapy; Type 2 diabetes; Diabetes prevention:
polymorphism; Type2 diabetes; Elderly patient 59, 219 Lifestyle factors; Prevention trials 59, 165
ISI composite; Insulinogenic index; HOMA-IR; HOMA - Plasma PAF acetylhydrolase; G994T polymorphism; Intima
cell 59. 71 media thickness; Type2 diabetes; Elderly patient 59, 219
Lifestyle factors; Type 2 diabetes; Diabetes prevention; Phar- Platelet aggregation; Non-insulin-dependent diabetes mellitus;
macotherapy; Prevention trials 59, 165 Zucker rats; Thromboxane A, vascular reactivity 59, 11
Lipoprotein(a); Type 2 diabetes mellitus; First-degree relatives; Postchallenge hyperglycemia; Hyperinsulinemia; Coronary
Dyslipidemia; Genetic correlation 59, 63 atherosclerosis; Angiographically documented 59, 129
Lipoprotein subclass; Diabetes mellitus; Remnant-like lipo- Postprandial blood glucose; Chronic renal failure; Nateglinide;
protein particles; Bezafibrate; Pravastatin; High performance Nateglinide metabolite 59, 191
liquid chromatography 59, 181
Postprandial glucose control; Fasting; Insulin; Lispro; Ra-
Lispro; Fasting; Insulin; Ramadan; Type 2 diabetes; Postpran- madan; Type 2 diabetes 59, 137
dial glucose control 59, 137
Postprandial hyperglycemia; Sucrase—isomaltase; Small intes-
tine; Disaccharidase; Oral hypoglycemic agent 59, 113
Medical records systems; Diabetes mellitus; Epidemiology;
Hospitalizations; Computerized 59, 145
Pravastatin; Diabetes mellitus; Remnant-like lipoprotein parti-
cles; Lipoprotein subclass; Bezafibrate; High performance liq-
Mesangial cells; Angiotensin II; Protein kinase C; Fibronectin;
Type IV collagen 59, 25 uid chromatography 59, 181
Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Mi- Prevention trials; Type 2 diabetes; Diabetes prevention;
tochondrial encephalomyopathy; Wolff—Parkinson— White Lifestyle factors; Pharmacotherapy 59, 165
syndrome; Sick sinus syndrome; Diabetic neuropathy; Dia-
betic retinopathy; Diabetic nephropathy 59, 207 Prospective study; Type | diabetes; Enterovirus; Beta-cell au-
toimmunity 59, 51
Mitochondrial encephalomyopathy; Mitochondrial DNA; Dia-
Protein kinase C; Angiotensin II; Fibronectin; Type IV colla-
betes mellitus; Insulin; Deafness; Wolff—Parkinson—White
syndrome; Sick sinus syndrome; Diabetic neuropathy; Dia- gen; Mesangial cells 59, 25
betic retinopathy; Diabetic nephropathy 59, 207
Ramadan; Fasting; Insulin; Lispro; Type 2 diabetes; Postpran-
NAD(P)H_ oxidase; Diabetes; Albuminuria; Dipyridamole; dial glucose control 59, 137
ACE inhibitor 59, 83
Remnant-like lipoprotein particles; Diabetes mellitus; Lipo-
Nateglinide; Chronic renal failure; Postprandial blood glucose; protein subclass; Bezafibrate; Pravastatin; High performance
Nateglinide metabolite 59, 191 liquid chromatography 59, 181
Nateglinide metabolite; Chronic renal failure; Postprandial Remodeling; Diabetes; Fibrosis; Interstitial space; Cross-
blood glucose; Nateglinide 59, 19] links 59, |
a Eeg ear
242 Subject index of volume 59
Repaglinide; Insulin secretion; Oxidative stress; Type 2 dia- Type 2 diabetes; Fasting; Insulin; Lispro; Ramadan; Postpran-
betes 59, 43 dial glucose control 59, 137
School children; Diabetes mellitus; Sex difference; Taiwan 59, Type 2 diabetes mellitus; Lipoprotein(a); First-degree relatives;
201 Dyslipidemia; Genetic correlation 59, 63
Sex difference; Diabetes mellitus; School children; Tai-
Type2 diabetes; Plasma PAF acetylhydrolase; G994T polymor-
wan 59, 201
phism; Intima media thickness; Elderly patient 59, 219
Sick sinus syndrome; Mitochondrial DNA; Diabetes mellitus;
Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff Type 2 diabetes; Repaglinide; Insulin secretion; Oxidative
Parkinson—White syndrome; Diabetic neuropathy; Diabetic stress 59, 43
retinopathy; Diabetic nephropathy 59, 207
Type 1 diabetes; Vitamin D receptor; Genotype; Genetic sus-
Small intestine; Sucrase—isomaltase; Disaccharidase; Oral hy- ceptibility; Dalmatia 59, 31
poglycemic agent; Postprandial hyperglycemia 59, 113
Type IV collagen; Angiotensin II; Protein kinase C; Fi-
Sucrase—isomaltase; Small intestine; Disaccharidase; Oral hy-
bronectin; Mesangial cells 59, 25
poglycemic agent; Postprandial hyperglycemia 59, 113
Ulcer; Diabetes; Foot; Amputation; Wound 59, 123
Taiwan; Diabetes mellitus; School children; Sex differ-
ence 59, 201
Vascular smooth muscle; Diabetes; High glucose; Angioplasty;
Tear function tests; Diabetes mellitus; Ocular surface disor- Growth factors; Coronary disease 59, 93
ders 59, 195
Vitamin D receptor; Genotype; Type | diabetes; Genetic sus-
Thromboxane A, vascular reactivity; Non-insulin-dependent ceptibility; Dalmatia 59, 31
diabetes mellitus; Zucker rats; Platelet aggregation 59, 11
Wolff—Parkinson—White syndrome; Mitochondrial DNA; Dia-
Type 2 diabetes; Acarbose; Elderly 59, 37
betes mellitus; Insulin; Deafness; Mitochondrial encephalomy-
opathy; Sick sinus syndrome; Diabetic neuropathy; Diabetic
Type 2 diabetes; Atherosclerosis; Augmentation 59, 153
retinopathy; Diabetic nephropathy 59, 207
Type 2 diabetes; Diabetes prevention; Lifestyle factors; Phar-
macotherapy; Prevention trials 59, 165 Wound; Diabetes; Foot; Ulcer; Amputation 59, 123
Type | diabetes; Enterovirus; Beta-cell autoimmunity; Prospec- Zucker rats; Non-insulin-dependent diabetes mellitus; Throm-
tive study 59, 51 boxane A, vascular reactivity; Platelet aggregation 59, 11